<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neonatal hyperglycemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neonatal hyperglycemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neonatal hyperglycemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann R Stark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca Simmons, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glucose supply and metabolism are of central importance for growth and normal brain development in the fetus and newborn. Disorders in glucose availability or utilization can result in hypoglycemia or hyperglycemia.</p><p>The causes and management of neonatal hyperglycemia are reviewed here. Other related topics include: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5053.html" rel="external">"Pathogenesis, screening, and diagnosis of neonatal hypoglycemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116267.html" rel="external">"Neonatal diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">DEFINITION</span></p><p class="headingAnchor" id="H87482346"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>Various definitions are used for hyperglycemia in neonates. Two common definitions are blood glucose (BG) &gt;125 mg/dL (6.9 mmol/L) or plasma glucose (the standard laboratory test) &gt;150 mg/dL (8.3 mmol/L). However, levels in this range are frequently observed among neonates receiving glucose infusions, especially extremely preterm infants, and may not require intervention [<a href="#rid1">1</a>].</p><p>Most neonatologists define clinically important hyperglycemia as BG &gt;180 to 200 mg/dL (10 to 11.1 mmol/L). At the authors’ institutions, this generally is the threshold used for intervention. (See <a class="local">'Management'</a> below.)</p><p>However, higher levels of hyperglycemia are required to produce hyperosmolality and osmotic diuresis. Plasma osmolality increases by 1 mosmol/L for each 18 mg/dL increase in plasma glucose concentration. Thus, a rise in glucose concentration from 110 to 200 mg/dL (6.1 to 11.1 mmol/L) only increases osmolality by 5 mosmol/L, which is a relatively small change.</p><p class="headingAnchor" id="H4"><span class="h2">Glucosuria</span><span class="headingEndMark"> — </span>Glucose excretion in the urine in hyperglycemic neonates is determined by the degree of hyperglycemia and renal tubular reabsorptive capacity for glucose. Newborns have variable reabsorptive capacities for glucose, which may be particularly reduced in those who are critically ill or preterm.</p><p>The net effect is that glucosuria alone is not a good marker for hyperglycemia since it can occur at normal blood glucose concentrations. For example, in one study of sick preterm infants born at 25 to 33 weeks gestation, fractional glucose excretion varied widely and glucosuria was often seen at normal blood glucose concentrations [<a href="#rid2">2</a>]. These variations presumably are related to immaturity of the proximal tubule.</p><p>On the other hand, mild hyperglycemia may be associated with little or no glucosuria in infants with mature proximal tubules. This was illustrated in a study of newborns who were given glucose infusions; at a mean blood glucose concentration of 197 mg/dL (11 mmol/L), there was little glucosuria and no significant osmotic diuresis [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Hyperglycemia typically occurs when a newborn cannot adapt to parenteral glucose infusion by decreasing endogenous glucose production or increasing peripheral glucose uptake [<a href="#rid4">4</a>]. This is usually related to an associated clinical condition such as extreme prematurity or sepsis.</p><p class="headingAnchor" id="H1509093742"><span class="h2">Normal glucose metabolism</span><span class="headingEndMark"> — </span>In both term and preterm infants, the following observations of glucose metabolism are seen [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic glucose production is suppressed by infusion of glucose (with or without amino acids), hyperglycemia, and insulin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucose production is not changed by intravenous (IV) lipid infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circulating insulin concentrations increase appropriately with hyperglycemia and increase hepatic and peripheral glucose uptake.</p><p></p><p class="headingAnchor" id="H1715083627"><span class="h2">Pathogenesis of hyperglycemia in preterm infants</span><span class="headingEndMark"> — </span>Hyperglycemia is more common in preterm infants compared with term infants. Although the mechanism(s) for the increased risk of hyperglycemia in preterm infants is uncertain, the following may be contributory factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired insulin response – Insulin responses may be inappropriately low in extremely low birth weight (ELBW) infants. In one study, 23 of 56 ELBW infants became hyperglycemic during IV glucose infusions that were incrementally increased to a maximum rate of 12 mg/kg per minute between days two and six of age [<a href="#rid5">5</a>]. Baseline insulin levels were similar in hyperglycemic and euglycemic infants, but only 15 of 23 hyperglycemic infants had a normal insulin response.</p><p></p><p class="bulletIndent1">The inappropriate insulin response in hyperglycemic ELBW infants may be related to defective islet beta cell processing of proinsulin. In a study comparing 15 hyperglycemic to 12 normoglycemic ELBW infants during the first week of life, proinsulin levels were significantly higher in the hyperglycemic ELBW infants, who also needed higher insulin levels to reach euglycemia compared with normoglycemic infants [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incomplete suppression of glucose production – Suppression of hepatic glucose production in response to glucose infusion also varies in very immature infants and may be incomplete. In a series of 10 infants born at 25 to 30 weeks gestation, glucose production rates decreased from 4.3 to 1.4 mg/kg per minute as glucose infusion was increased from 1.7 to 6.5 mg/kg per minute [<a href="#rid7">7</a>]. Plasma concentrations of glucose and insulin also increased.</p><p></p><p class="bulletIndent1">Proteolysis due to negative nitrogen balance, which occurs more commonly in the preterm infant, may also be a stimulus for inappropriate glucose production. For example, in ELBW infants, insufficient protein intake results in endogenous protein loss (proteolysis) in an effort to meet the basal metabolic needs of the infant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased secretion of counterregulatory hormones associated with stress – Secretion of epinephrine and cortisol in stressed infants may contribute to hyperglycemia. The role of stress was demonstrated in a report of metabolic responses to glucose infusion in preterm infants (weight 700 to 1550 g) [<a href="#rid8">8</a>]. Measurements were made before and after infusion in controls and in infants who required assisted ventilation and were considered stressed. Stressed infants had higher levels of glucose and of cortisol compared with controls and were more likely to have hyperglycemia (13 of 18 versus 1 of 12 infants). This difference was not due to decreased insulin or increased cortisol levels, because, among the stressed infants, insulin levels were higher and cortisol levels lower in the hyperglycemic compared with the euglycemic newborns. (See  <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus", section on 'Counterregulatory hormones'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>In general, neonatal hyperglycemia is associated with a clinical condition, rather than a specific disorder of glucose metabolism, and it occurs mostly in infants receiving intravenous (IV) glucose infusions. A rare cause of hyperglycemia is neonatal diabetes mellitus, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116267.html" rel="external">"Neonatal diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H16460511"><span class="h2">Parenteral administration of glucose</span><span class="headingEndMark"> — </span>Many preterm or acutely ill neonates receive IV glucose because enteral feeding is insufficient or delayed. Neonatal hyperglycemia often occurs in this setting because of changes in glucose requirements and metabolism. Often, there are multiple factors (eg, sepsis, extreme prematurity, and stress) that affect glucose metabolism and increase the risk of hyperglycemia.</p><p>Immediately after birth, IV glucose is typically provided at a rate of 5 to 8 mg/kg per minute to avoid hypoglycemia for neonates who will not be fed enterally. In most settings, sufficient glucose at a rate of 7 mg/kg per minute is provided by the administration of 10 percent dextrose solution at 100 mL/kg per day. Although dextrose is a hydrated form of glucose and is 91 percent glucose, the correction usually is not applied in clinical practice. The glucose infusion rate is increased to approximately 11 to 12 mg/kg per minute in the first two to three days after birth to provide calories for growth. In general, glucose infusion rates &gt;15 mg/kg per minute are avoided, as this exceeds the ability of most infants to oxidize glucose and may promote excessive lipogenesis [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants", section on 'Energy requirements'</a>.)</p><p>Additional risk factors associated with hyperglycemia for infants who receive parenteral glucose includes increasing prematurity, intrauterine growth restriction, sepsis, and stress [<a href="#rid1">1,9</a>].</p><p class="headingAnchor" id="H1923912171"><span class="h3">Prematurity</span><span class="headingEndMark"> — </span>Hyperglycemia during glucose infusion is common in preterm infants and the risk increases with decreasing gestational age [<a href="#rid9">9-12</a>]. Extremely preterm (gestational age &lt;28 weeks) and extremely low birth weight (ELBW; BW &lt;1000 g) infants frequently develop hyperglycemia even in the absence of high rates of glucose infusion [<a href="#rid13">13</a>]. In one prospective study that included 580 EPT neonates, 70 percent experienced hyperglycemia (defined as blood glucose &gt;180 mg/dL [10 mmol/L]) at least once during the first 28 days and nearly half had persistent hyperglycemia for ≥2 days [<a href="#rid14">14</a>]. </p><p>Proposed underlying mechanisms include reduced insulin secretion, incomplete suppression of hepatic glucose production, defective insulin secretion, and stress response resulting in counter hormone regulation [<a href="#rid6">6</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H1700891557"><span class="h3">Sepsis</span><span class="headingEndMark"> — </span>Hyperglycemia may be a nonspecific presenting sign of sepsis in an infant with previously normal blood glucose concentrations. Potential mechanisms include the stress response, decreased insulin release, and reduced peripheral utilization of glucose [<a href="#rid15">15</a>]. In the very low birth weight preterm infant (birth weight &lt;1500 g), fungal rather than bacterial sepsis appears to be more commonly associated with hyperglycemia [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H369418768"><span class="h3">Stress</span><span class="headingEndMark"> — </span>The stress response to critical illness with the release of counter regulatory hormones (eg, epinephrine and cortisol) may result in hyperglycemia, especially in preterm infants who require mechanical ventilation. There is limited evidence that increased severity of respiratory distress and metabolic acidosis requiring medical intervention (eg, administration of bicarbonate) is linked to an increased risk of hyperglycemia [<a href="#rid1">1</a>]. The stress response also may be responsible for hyperglycemia occurring after surgery. In this setting, increased rates of fluid administration containing dextrose may also be a contributory factor.</p><p class="headingAnchor" id="H11"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Hyperglycemia is a common complication of glucocorticoid therapy, especially in ELBW infants [<a href="#rid17">17</a>]. Hyperglycemia can also occur following administration of methylxanthines [<a href="#rid18">18</a>], <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a> (the mechanism may be suppression of insulin release or insulin insensitivity) [<a href="#rid19">19</a>] and beta-adrenergic agents (eg, <a class="drug drug_pediatric" data-topicid="13248" href="/z/d/drug information/13248.html" rel="external">dopamine</a>, epinephrine and <a class="drug drug_pediatric" data-topicid="12650" href="/z/d/drug information/12650.html" rel="external">norepinephrine</a>) [<a href="#rid20">20</a>]. Hyperglycemia is almost always mild in these cases and does not require therapy. If the infant is on IV fluids, the glucose infusion rate (GIR) can be reduced. </p><p class="headingAnchor" id="H12"><span class="h2">Neonatal diabetes mellitus</span><span class="headingEndMark"> — </span>Neonatal diabetes mellitus (DM) is a rare cause of hyperglycemia. It is defined as persistent hyperglycemia occurring in the first months of life that lasts more than two weeks and requires insulin for management. Neonatal DM is a monogenic disorder caused by a mutation in genes that encode proteins that affect pancreatic beta cell function.</p><p>The etiology, evaluation and management of neonatal DM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116267.html" rel="external">"Neonatal diabetes mellitus"</a>.) </p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Neonatal hyperglycemia is primarily observed in neonates receiving parenteral glucose infusion, especially preterm infants. As a result, management is focused on reducing blood glucose (BG) levels to target levels while maintaining adequate caloric intake for those patients who are dependent on parenteral nutrition (PN).</p><p class="headingAnchor" id="H4148454607"><span class="h2">Our approach</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine monitoring</strong> – All patients receiving intravenous (IV) glucose should have routine monitoring of BG levels. For most infants, daily monitoring is sufficient. However, more frequent monitoring is warranted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extremely low birth weight (ELBW) infants (BW &lt;1000 g) </p><p class="bulletIndent2"><span class="glyph">•</span>Infants with critical illness, sepsis, or other stress</p><p class="bulletIndent2"><span class="glyph">•</span>Infants receiving insulin infusion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional sources of energy intake </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amino acid and lipid infusion – For infants requiring IV glucose, we suggest administering amino acid solution and lipid emulsion to provide substrate for gluconeogenesis, spare glucose utilization, and stimulate insulin release. Although data are limited, a retrospective study demonstrated that nutritional changes aimed at providing more protein and less fat and carbohydrates resulted in a lower mean blood glucose concentration and less frequent episodes of hyperglycemia without increasing the risk of hypoglycemia [<a href="#rid21">21</a>]. These issues are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enteral feeds – Enteral feeding is initiated as soon as possible in order to wean and discontinue PN. Enteral feeds promote the gastric release of glucose-dependent insulinotropic peptide (GIP) and GLP-1, incretin hormones that promote insulin secretion from the pancreas [<a href="#rid22">22,23</a>]. Gastrointestinal incretin-mediated insulin release in response to orogastric administration of a glucose load may occur when a threshold of glucose concentration has exceeded 105 mg/dL. The approach to initiating enteral feeds is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation if hyperglycemia occurs</strong> – For neonates who have documented hyperglycemia (ie, BG &gt;180 mg/dL [10 mmol/L), we take the following steps: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications are reviewed and any drugs that may be contributing to hyperglycemia are discontinued, if possible. Examples include glucocorticoids, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, and beta-adrenergic agents. (See <a class="local">'Drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with signs and symptoms of sepsis, blood cultures are obtained and empiric antibiotics are administered, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a> and  <a class="medical medical_review" href="/z/d/html/89456.html" rel="external">"Treatment and prevention of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Empiric antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial interventions</strong> – For patients receiving IV glucose infusions (including PN) who develop hyperglycemia, our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with BG &gt;180 to 200 mg/dL (10 to 11.1 mmol/L), the first step is to reduce the glucose infusion rate (GIR) to 4 to 6 mg/kg per minute. This is accomplished by decreasing the dextrose concentration in the fluid. However, a minimum dextrose concentration of 5 percent should be maintained. (See <a class="local">'Lowering the GIR'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For neonates with persistent hyperglycemia (BG &gt;200 mg/dL [11.1 mmol/L]) despite reducing the GIR, and for those with poor weight gain because of reduced caloric intake from low GIR, we suggest insulin therapy. (See <a class="local">'Insulin therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H2795005469"><span class="h2">Specific interventions</span></p><p class="headingAnchor" id="H87482770"><span class="h3">Lowering the GIR</span><span class="headingEndMark"> — </span>For neonates receiving IV glucose (including those receiving PN) who have BG levels &gt;180 to 200 mg/dL (10 to 11.1 mmol/L), the first step in management is to decrease the GIR to 4 to 6 mg/kg per minute. This usually successfully lowers the BG level to an acceptable range. In most cases, the GIR is lowered by reducing the concentration of the dextrose in the fluid from 10 to 5 percent. For infants receiving IV glucose in PN, normoglycemia can usually be maintained despite the reduced glucose supply because there are other nutrients that act as a substrate for gluconeogenesis (ie, amino acids and lipids) [<a href="#rid24">24</a>]. </p><p>However, reducing the GIR is a short-term solution because it results in decreased caloric intake and compromises growth. Glucose tolerance typically improves when enteral feedings are established. (See  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Insulin therapy</span><span class="headingEndMark"> — </span>For infants who remain hyperglycemic despite reducing the GIR, we suggest insulin therapy. Insulin improves glucose utilization, reduces blood glucose levels, allows provision of more calories, and promotes growth. </p><p class="headingAnchor" id="H1383438005"><span class="h4">Indications</span><span class="headingEndMark"> — </span>While indications for insulin therapy are not standardized, most neonatologists, including the authors of this topic, begin insulin therapy in infants who meet either of the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent hyperglycemia (&gt;200 mg/dL [11.1 mmol/L]) despite reduced GIR</p><p class="bulletIndent1"><span class="glyph">●</span>Poor weight gain because of low caloric intake from low GIR</p><p></p><p>The efficacy and safety of insulin therapy for treating hyperglycemia in preterm neonates is supported by observational studies and a few small clinical trials that were carried out in the 1990s [<a href="#rid5">5,14,25,26</a>]. In a clinical trial involving 24 neonates with hyperglycemia who were randomly assigned insulin therapy or standard care alone, those assigned to insulin therapy tolerated treatment well and had greater energy intake and better weight gain compared with those in the control group [<a href="#rid25">25</a>]. The trial was underpowered to detect differences in other clinical outcomes (mortality or long-term morbidity). In a prospective study that included 80 extremely preterm (EPT) infants who were treated with insulin and 500 EPT infants managed without insulin, insulin therapy was independently associated with lower 70-day mortality after adjusting for confounding factors (odds ratio [OR] 0.34, 95% CI 0.14-0.85) [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H447363088"><span class="h4">Dosing and administration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and titration</strong> – Insulin therapy in neonates consists of <a class="drug drug_pediatric" data-topicid="12880" href="/z/d/drug information/12880.html" rel="external">regular insulin</a> diluted in normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> to a concentration of 0.1 units/mL or 0.5 units/mL. Dosing is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An initial bolus is given at a dose of 0.05 to 0.1 units/kg IV over 15 minutes. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The BG level is then monitored every 30 to 60 minutes. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If BG remains elevated, the bolus insulin dose can be repeated every four to six hours for up to three doses. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the BG remains elevated after three bolus doses of insulin, we suggest continuous infusion of insulin at an initial dose of 0.01 to 0.05 units/kg per hour IV. The infusion rate is adjusted in increments of 0.01 units/kg per hour as needed up to a maximum dose of 0.1 units/kg per hour to maintain BG levels in the target range (150 to &lt;200 mg/dL [8.3 to 11 mmol/L]). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If BG levels remains &lt;150 mg/dL (8.3 mmol/L), the infusion can be decreased in increments of 0.01 to 0.05 units/kg per hour. The infusion can be discontinued once BG levels are stable at values &lt;150 mg/dL (8.3 mmol/L) on the lowest infusion dose. BG levels should continue to be monitored closely for the next 12 to 24 hours after discontinuing the infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Other important aspects of administration of insulin infusions in neonates include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plastic tubing used for infusion should be primed with insulin for at least 20 minutes before treatment because insulin nonspecifically binds to the tubing, resulting in decreased availability to the patient. In one report, recovery of insulin from effluent of primed polyvinyl chloride tubing at a flow rate of 0.2 mL/hour was greater at one, two, four, and eight hours compared with unprimed tubing (42, 85, 91, and 95 versus 22, 38, 67, and 75 percent, respectively) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The solution should be changed at least every 24 hours or according to the hospital’s pharmacy protocol.</p><p></p><p class="headingAnchor" id="H2142301302"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>BG levels should be monitored within 30 minutes to 1 hour of the start of the infusion and after any changes in the GIR or insulin infusion. BG should be monitored hourly until stable, and then less frequently.</p><p class="headingAnchor" id="H4126635273"><span class="h4">Target BG range</span><span class="headingEndMark"> — </span>For most neonates managed with insulin therapy, we suggest a target BG range of 150 to &lt;200 mg/dL (8.3 to &lt;11 mmol/L). We do not aim for tight glycemic control (BG &lt;150 mg/dL [8.3 mmol/L]) since this substantially increases the risk of hypoglycemia without any apparent short- or long-term benefits [<a href="#rid28">28,29</a>].</p><p>In a clinical trial of 88 very low birth weight (VLBW) infants who were randomly assigned to tight glycemic control (target BG 70 to 110 mg/dL [4 to 6 mmol/L]) or standard care (target BG 145 to 180 mg/dL [8 to 10 mmol/L]), those assigned to tight glycemic control experienced hypoglycemia (defined as BG &lt;47 mg/dL [2.6 mmol/L]) at a more than two-fold higher rate than those managed with standard care (58 versus 27 percent, respectively) [<a href="#rid28">28</a>]. Mortality rates were similar in both groups (12 versus 9 percent, respectively) as were rates of other neonatal morbidities (eg, sepsis, necrotizing enterocolitis, intraventricular hemorrhage).</p><p class="headingAnchor" id="H19"><span class="h4">Risk of hypoglycemia</span><span class="headingEndMark"> — </span>In studies of neonates receiving insulin therapy for treatment of hyperglycemia, reported rates of hypoglycemia (typically defined as BG &lt;47 mg/dL [2.6 mmol/L]) range from 0 to 27 percent [<a href="#rid28">28,30-34</a>]. The wide range likely reflects differences in the populations studied (the risk is highest in extremely low birth weight infants) and the method used for detecting hypoglycemia (rates are generally higher in studies using continuous BG monitoring). In addition, the risk of hypoglycemia is considerably higher when insulin is used to treat normoglycemic neonates, as discussed below. (See <a class="local">'No role for routine early insulin therapy'</a> below.)</p><p>For neonates who develop significant hypoglycemia while receiving insulin therapy, management consists of stopping the insulin infusion and administering <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a> (2 mL/kg of 10% dextrose in water [D10W] given IV over 5 to 15 minutes). (See  <a class="medical medical_review" href="/z/d/html/101425.html" rel="external">"Management and outcome of neonatal hypoglycemia", section on 'IV dextrose infusion'</a>.) </p><p class="headingAnchor" id="H445043194"><span class="h4">No role for routine early insulin therapy</span><span class="headingEndMark"> — </span>Routine early use of insulin therapy (ie, administering insulin even in the absence of documented hyperglycemia) has been proposed as a strategy for preventing catabolism, improving glucose control, increasing energy intake, and possibly improving growth in preterm infants. However, based upon the available data, routine insulin therapy does <strong>not</strong> appear to provide any benefit compared with standard care and it may be harmful [<a href="#rid30">30</a>]. Thus, we suggest the stepwise approach described above and reserve insulin therapy for neonates who have persistent hyperglycemia despite lowering the GIR. (See <a class="local">'Our approach'</a> above.)</p><p>The efficacy and safety of routine early insulin therapy was evaluated in the NIRTURE (Neonatal Insulin Replacement Therapy in Europe) trial, which enrolled 389 very low birth weight (VLBW) infants (BW &lt;1500 g) who were randomly assigned to either early insulin therapy or standard care [<a href="#rid30">30</a>]. Early insulin therapy consisted of a fixed dose of insulin (0.05 units/kg per hour) started within 24 hours of birth and continued until seven days of age; insulin was given in conjunction with IV infusion of 20 percent dextrose as needed to maintain euglycemia. Neonates in the standard care group received insulin only if two consecutive BG levels were &gt;180 mg/dL (10 mmol/L), which occurred in 36 percent of patients. The trial was stopped early because of concerns for potential harm from early insulin therapy. At 28 days, mortality was lower in the standard care group compared with the early insulin group (6 versus 12 percent, respectively; OR 0.45, 95% CI 0.21-0.96). Mortality was also lower in the control group at 40 weeks postmenstrual age, but the difference was not statistically significant (9 versus 14 percent; OR 0.61, 95% CI 0.33-1.15). Episodes of hypoglycemia (defined as BG &lt;47 mg/dL [2.6 mmol/L] for &gt;1 hour) occurred in the early insulin group at a rate that was approximately twice that of the control group (29 versus 17 percent, respectively; OR 2.2, 95% CI 1.34-3.65). Of note, the rate of hypoglycemia in this study was substantially higher than in other studies describing use of insulin in preterm neonates. This is likely explained by NIRTUREꞌs use of continuous glucose monitoring, which has a higher sensitivity for detecting hypoglycemic episodes compared with routine intermittent monitoring. (See <a class="local">'Risk of hypoglycemia'</a> above.)</p><p class="headingAnchor" id="H87482572"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>While neonatal hyperglycemia is associated with adverse short- and long-term outcomes, it is unclear if it has a causal role in contributing to morbidity and mortality in this population or if it is merely a marker for disease severity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – Neonatal hyperglycemia is associated with increased mortality risk [<a href="#rid10">10,11,14,35-38</a>]. In a meta-analysis of six observational studies including 1696 preterm neonates, hyperglycemia was associated with a more than two-fold increase in the risk of mortality (adjusted odds ratio [OR] 2.4, 95% CI 1.4-4.0) [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurodevelopment outcome </strong>– Observational data suggest that neonatal hyperglycemia is associated with increased risk of neurodevelopmental impairment (NDI) [<a href="#rid33">33,38-40</a>]. In the meta-analysis described above, neonatal hyperglycemia was associated with increased risk of severe intraventricular hemorrhage (OR 1.9, 95% CI 1.4-2.5; based on nine studies) and increased risk of long-term disability (OR 2.4, 95% CI 1.5-3.7; based on three studies) [<a href="#rid38">38</a>]. As with mortality, it is unclear whether these associations are causal of if hyperglycemia is merely a marker for disease severity.</p><p></p><p class="bulletIndent1">Neurodevelopmental outcomes for neonates with hyperglycemia depend largely on the gestational age and other comorbidities. (See  <a class="medical medical_review" href="/z/d/html/4967.html" rel="external">"Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors"</a>.)</p><p></p><p>Further research, including clinical trials to clarify the role of insulin, is needed to provide a better understanding of the consequences of hyperglycemia and determine which infants require intervention.</p><p class="headingAnchor" id="H5121848"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The increased risk of hyperglycemia (defined as glucose levels &gt;125 mg/dL [6.9 mmol/L]) in preterm infants compared with term infants is thought to be due to impaired insulin response, incomplete suppression of hepatic glucose production, and increased secretion of counterregulatory hormones associated with stress. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – The most common cause of neonatal hyperglycemia is administration of intravenous (IV) glucose, especially in very low birth weight (VLBW) infants (BW &lt;1500 g). Other contributing conditions include the stress response to critical illness, sepsis, and drugs associated with hyperglycemia (eg, <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">phenytoin</a>, glucocorticoids, beta-adrenergic agents). A rare cause of neonatal hyperglycemia is neonatal diabetes mellitus, which is discussed separately. (See <a class="local">'Causes'</a> above and  <a class="medical medical_review" href="/z/d/html/116267.html" rel="external">"Neonatal diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine monitoring</strong> – All patients receiving IV glucose should have routine monitoring of blood glucose (BG) levels. For most infants, daily monitoring is sufficient. However, more frequent monitoring is warranted in (see <a class="local">'Our approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extremely low birthweight (ELBW) infants (BW &lt;1000 g)</p><p class="bulletIndent2"><span class="glyph">•</span>Infants with critical illness, sepsis, or other stress</p><p class="bulletIndent2"><span class="glyph">•</span>Infants receiving insulin infusion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – For neonates who have documented hyperglycemia (BG &gt;180 mg/dL [10 mmol/L]), we suggest the following stepwise management approach (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Address potential underlying causes</strong> – If possible, drugs that cause hyperglycemia are discontinued. (See <a class="local">'Drugs'</a> above.)</p><p></p><p class="bulletIndent2">For patients with signs and symptoms of sepsis, blood cultures are obtained and empiric antibiotics are administered, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/z/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Provide additional sources of energy intake</strong> – For infants receiving IV glucose through parenteral nutrition (PN), amino acid solution and lipid emulsion are also provided as substrate for gluconeogenesis. Enteral feeding is initiated as soon as possible in order to wean and discontinue PN. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants"</a> and  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reduce the glucose infusion rate (GIR)</strong> – For most neonates with hyperglycemia, we suggest reducing the GIR to 4 to 6 mg/kg per minute as the initial intervention rather than early insulin therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is accomplished by decreasing the dextrose concentration in the IV fluid or PN solution. However, a minimum dextrose concentration of 5 percent should be maintained. (See <a class="local">'Lowering the GIR'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insulin therapy</strong> – For neonates with persistent hyperglycemia (BG &gt;200 mg/dL [11.1 mmol/L]) despite reducing the GIR, and for those with poor weight gain because of reduced caloric intake from low GIR, we suggest insulin therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Insulin therapy'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing</strong> – <a class="drug drug_pediatric" data-topicid="12880" href="/z/d/drug information/12880.html" rel="external">Regular insulin</a> is initially administered as a bolus of 0.05 to 0.1 units/kgi IV over 15 minutes. BG levels are then monitored every 30 to 60 minutes. If needed, the bolus dose can be repeated every four to six hours for up to three doses. If the BG remains elevated after three bolus doses of insulin, a continuous insulin infusion is started at an initial dose of 0.01 to 0.05 units/kg per hour IV. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monitoring</strong> – BG levels should be monitored within 30 minutes to 1 hour of the start of the infusion and after any changes in the GIR or insulin infusion. BG levels should be monitored hourly until stable, and then less frequently. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Target BG levels</strong> – For most neonates managed with insulin therapy, we suggest a target BG range of 150 to &lt;200 mg/dL (8.3 to &lt;11 mmol/L) rather than aiming for tight glycemic control (BG &lt;150 mg/dL [8.3 mmol/L]) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Target BG range'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Neonatal hyperglycemia is associated with increased risk of adverse short- and long-term outcomes; however, it is unclear if it has a causal role in contributing to morbidity and mortality in this population or if it is merely a marker for disease severity. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="headingAnchor" id="H16460503"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges See Wai Chan, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Louik C, Mitchell AA, Epstein MF, Shapiro S. Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion. Am J Dis Child 1985; 139:783.</a></li><li><a class="nounderline abstract_t">Wilkins BH. Renal function in sick very low birthweight infants: 4. Glucose excretion. Arch Dis Child 1992; 67:1162.</a></li><li><a class="nounderline abstract_t">Cowett RM, Oh W, Schwartz R. Persistent glucose production during glucose infusion in the neonate. J Clin Invest 1983; 71:467.</a></li><li class="breakAll">Kalhan SC, Devaskar SU. Disorders of carbohydrate metabolism. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.1497.</li><li><a class="nounderline abstract_t">Meetze W, Bowsher R, Compton J, Moorehead H. Hyperglycemia in extremely- low-birth-weight infants. Biol Neonate 1998; 74:214.</a></li><li><a class="nounderline abstract_t">Mitanchez-Mokhtari D, Lahlou N, Kieffer F, et al. Both relative insulin resistance and defective islet beta-cell processing of proinsulin are responsible for transient hyperglycemia in extremely preterm infants. Pediatrics 2004; 113:537.</a></li><li><a class="nounderline abstract_t">Sunehag A, Gustafsson J, Ewald U. Very immature infants (&lt; or = 30 Wk) respond to glucose infusion with incomplete suppression of glucose production. Pediatr Res 1994; 36:550.</a></li><li><a class="nounderline abstract_t">Lilien LD, Rosenfield RL, Baccaro MM, Pildes RS. Hyperglycemia in stressed small premature neonates. J Pediatr 1979; 94:454.</a></li><li><a class="nounderline abstract_t">Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study. J Pediatr 2010; 157:715.</a></li><li><a class="nounderline abstract_t">Alexandrou G, Skiöld B, Karlén J, et al. Early hyperglycemia is a risk factor for death and white matter reduction in preterm infants. Pediatrics 2010; 125:e584.</a></li><li><a class="nounderline abstract_t">Kao LS, Morris BH, Lally KP, et al. Hyperglycemia and morbidity and mortality in extremely low birth weight infants. J Perinatol 2006; 26:730.</a></li><li><a class="nounderline abstract_t">Blanco CL, Baillargeon JG, Morrison RL, Gong AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26:737.</a></li><li><a class="nounderline abstract_t">Farrag HM, Cowett RM. Glucose homeostasis in the micropremie. Clin Perinatol 2000; 27:1.</a></li><li><a class="nounderline abstract_t">Zamir I, Tornevi A, Abrahamsson T, et al. Hyperglycemia in Extremely Preterm Infants-Insulin Treatment, Mortality and Nutrient Intakes. J Pediatr 2018; 200:104.</a></li><li><a class="nounderline abstract_t">White RH, Frayn KN, Little RA, et al. Hormonal and metabolic responses to glucose infusion in sepsis studied by the hyperglycemic glucose clamp technique. JPEN J Parenter Enteral Nutr 1987; 11:345.</a></li><li><a class="nounderline abstract_t">Manzoni P, Castagnola E, Mostert M, et al. Hyperglycaemia as a possible marker of invasive fungal infection in preterm neonates. Acta Paediatr 2006; 95:486.</a></li><li><a class="nounderline abstract_t">Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 10:CD001146.</a></li><li><a class="nounderline abstract_t">Srinivasan G, Singh J, Cattamanchi G, et al. Plasma glucose changes in preterm infants during oral theophylline therapy. J Pediatr 1983; 103:473.</a></li><li><a class="nounderline abstract_t">al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med 1991; 8:968.</a></li><li><a class="nounderline abstract_t">Rozance PJ and. Neonatal hyperglycemia. NeoReviews 2010; 11:e632.</a></li><li><a class="nounderline abstract_t">Tottman AC, Bloomfield FH, Cormack BE, et al. Relationships Between Early Nutrition and Blood Glucose Concentrations in Very Preterm Infants. J Pediatr Gastroenterol Nutr 2018; 66:960.</a></li><li><a class="nounderline abstract_t">Shanahan KH, Yu X, Miller LG, et al. Early Serum Gut Hormone Concentrations Associated With Time to Full Enteral Feedings in Preterm Infants. J Pediatr Gastroenterol Nutr 2018; 67:97.</a></li><li><a class="nounderline abstract_t">Lucas A, Bloom SR, Aynsley-Green A. Gut hormones and 'minimal enteral feeding'. Acta Paediatr Scand 1986; 75:719.</a></li><li><a class="nounderline abstract_t">Sunehag AL, Haymond MW, Schanler RJ, et al. Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition. Diabetes 1999; 48:791.</a></li><li><a class="nounderline abstract_t">Collins JW Jr, Hoppe M, Brown K, et al. A controlled trial of insulin infusion and parenteral nutrition in extremely low birth weight infants with glucose intolerance. J Pediatr 1991; 118:921.</a></li><li><a class="nounderline abstract_t">Bottino M, Cowett RM, Sinclair JC. Interventions for treatment of neonatal hyperglycemia in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD007453.</a></li><li><a class="nounderline abstract_t">Fuloria M, Friedberg MA, DuRant RH, Aschner JL. Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. Pediatrics 1998; 102:1401.</a></li><li><a class="nounderline abstract_t">Alsweiler JM, Harding JE, Bloomfield FH. Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial. Pediatrics 2012; 129:639.</a></li><li><a class="nounderline abstract_t">Tottman AC, Alsweiler JM, Bloomfield FH, et al. Long-Term Outcomes of Hyperglycemic Preterm Infants Randomized to Tight Glycemic Control. J Pediatr 2018; 193:68.</a></li><li><a class="nounderline abstract_t">Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Early insulin therapy in very-low-birth-weight infants. N Engl J Med 2008; 359:1873.</a></li><li><a class="nounderline abstract_t">Binder ND, Raschko PK, Benda GI, Reynolds JW. Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia. J Pediatr 1989; 114:273.</a></li><li><a class="nounderline abstract_t">Vaucher YE, Walson PD, Morrow G 3rd. Continuous insulin infusion in hyperglycemic, very low birth weight infants. J Pediatr Gastroenterol Nutr 1982; 1:211.</a></li><li><a class="nounderline abstract_t">Patidar N, Rath CP, Rao S, Patole S. Outcomes of very preterm infants with hyperglycaemia treated with insulin: A systematic review and meta-analysis. Acta Paediatr 2023; 112:1157.</a></li><li><a class="nounderline abstract_t">Heald A, Abdel-Latif ME, Kent AL. Insulin infusion for hyperglycaemia in very preterm infants appears safe with no effect on morbidity, mortality and long-term neurodevelopmental outcome. J Matern Fetal Neonatal Med 2012; 25:2415.</a></li><li><a class="nounderline abstract_t">Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics 2006; 118:1811.</a></li><li><a class="nounderline abstract_t">Stensvold HJ, Strommen K, Lang AM, et al. Early Enhanced Parenteral Nutrition, Hyperglycemia, and Death Among Extremely Low-Birth-Weight Infants. JAMA Pediatr 2015; 169:1003.</a></li><li><a class="nounderline abstract_t">Auerbach A, Eventov-Friedman S, Arad I, et al. Long duration of hyperglycemia in the first 96 hours of life is associated with severe intraventricular hemorrhage in preterm infants. J Pediatr 2013; 163:388.</a></li><li><a class="nounderline abstract_t">Rath CP, Shivamallappa M, Muthusamy S, et al. Outcomes of very preterm infants with neonatal hyperglycaemia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2022; 107:269.</a></li><li><a class="nounderline abstract_t">Zamir I, Stoltz Sjöström E, Ahlsson F, et al. Neonatal hyperglycaemia is associated with worse neurodevelopmental outcomes in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2021; 106:460.</a></li><li><a class="nounderline abstract_t">Gonzalez Villamizar JD, Haapala JL, Scheurer JM, et al. Relationships between Early Nutrition, Illness, and Later Outcomes among Infants Born Preterm with Hyperglycemia. J Pediatr 2020; 223:29.</a></li></ol></div><div id="topicVersionRevision">Topic 4981 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4025257" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1444549" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Renal function in sick very low birthweight infants: 4. Glucose excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338038" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Persistent glucose production during glucose infusion in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338038" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Persistent glucose production during glucose infusion in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691162" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hyperglycemia in extremely- low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993546" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Both relative insulin resistance and defective islet beta-cell processing of proinsulin are responsible for transient hyperglycemia in extremely preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7816531" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Very immature infants (&lt;or = 30 Wk) respond to glucose infusion with incomplete suppression of glucose production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/423036" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hyperglycemia in stressed small premature neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570286" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence and determinants of hyperglycemia in very low birth weight infants: cohort analyses of the NIRTURE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176674" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Early hyperglycemia is a risk factor for death and white matter reduction in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929344" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hyperglycemia and morbidity and mortality in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929343" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690562" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Glucose homeostasis in the micropremie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29731360" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hyperglycemia in Extremely Preterm Infants-Insulin Treatment, Mortality and Nutrient Intakes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3112425" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hormonal and metabolic responses to glucose infusion in sepsis studied by the hyperglycemic glucose clamp technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720499" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hyperglycaemia as a possible marker of invasive fungal infection in preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29063585" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Early (&lt;8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886917" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Plasma glucose changes in preterm infants during oral theophylline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1838051" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phenytoin-induced insulin insensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neonatal hyperglycemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481441" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relationships Between Early Nutrition and Blood Glucose Concentrations in Very Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620597" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early Serum Gut Hormone Concentrations Associated With Time to Full Enteral Feedings in Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3105234" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gut hormones and 'minimal enteral feeding'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1904090" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A controlled trial of insulin infusion and parenteral nutrition in extremely low birth weight infants with glucose intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975769" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interventions for treatment of neonatal hyperglycemia in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832576" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430450" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198539" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-Term Outcomes of Hyperglycemic Preterm Infants Randomized to Tight Glycemic Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971490" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early insulin therapy in very-low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492598" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6764506" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Continuous insulin infusion in hyperglycemic, very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36895111" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcomes of very preterm infants with hyperglycaemia treated with insulin: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22668010" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Insulin infusion for hyperglycaemia in very preterm infants appears safe with no effect on morbidity, mortality and long-term neurodevelopmental outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079549" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348113" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early Enhanced Parenteral Nutrition, Hyperglycemia, and Death Among Extremely Low-Birth-Weight Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23472766" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long duration of hyperglycemia in the first 96 hours of life is associated with severe intraventricular hemorrhage in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34330757" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Outcomes of very preterm infants with neonatal hyperglycaemia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33863775" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neonatal hyperglycaemia is associated with worse neurodevelopmental outcomes in extremely preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32532652" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Relationships between Early Nutrition, Illness, and Later Outcomes among Infants Born Preterm with Hyperglycemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
